Abstracts tagged "lymphopenia"

Abstract Number: 2875 • 2019 ACR/ARP Annual Meeting
Effects of Filgotinib on Anemia, Thrombocytopenia and Leukopenia: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biological DMARDs
Mark Genovese¹, Kenneth Kalunian ², Jacques-Eric Gottenberg ³, Beatrix Bartok ⁴, YingMeei Tan ⁴, Ying Guo ⁴, Chantal Tasset ⁵, John Sundy ⁴, Kurt de Vlam ⁶, David Walker ⁷ and Tsutomu Takeuchi ⁸, ¹Stanford University, Stanford, CA, ²Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ³Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁷Northumbria Healthcare, Northumbria, United Kingdom, ⁸Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Anemia, thrombocytopenia and leukopenia in RA patients treated with non-Janus Kinase 1 (JAK1) selective inhibitors may be due to inhibition of hematopoietic growth factors…
Abstract Number: 1822 • 2016 ACR/ARHP Annual Meeting
CD4+ T Cell Lymphopenia Is Associated with Deficient Ubiquitination of the Cell Cycle Inhibibitor p27kip1 By the E3 Ligase Casitas B-Lineage Lymphoma-b in Patients with Systemic Lupus Erythematosus
Diana Gómez-Martín, Jorge Romo-Tena, Javier Merayo-Chalico and Jorge Alcocer-Varela, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Lymphopenia has been associated with the development of autoimmune diseases. Particularly, in patients with Systemic Lupus Erythematosus (SLE) is a common clinical feature. However,…
Abstract Number: 1762 • 2015 ACR/ARHP Annual Meeting
Reciprocal Roles of Intestinal Microbiota in the Pathogenesis of Organ-Specific Autoimmune Diseases in a Lymphopenia-Induced Autoimmunity Mouse Model
Toshiki Eri¹, Kimito Kawahata², Ei Bannai¹, Takeyuki Kanzaki³, Lisa Akahira¹, Kazuya Michishita¹ and Kazuhiko Yamamoto¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ³Internal Medicine, Yamanashi Prefectural Central Hospital, Yamanashi, Japan
Background/Purpose: Past studies reported lymphopenia mouse transfer model which transfer CD4+CD25- cells from wild-type BALB/c mouse into athymic nude BALB/c mice produce lupus-like systemic autoantibodies…
Abstract Number: 2990 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus Patients: A Single Center Study
Javier Merayo-Chalico¹, Elia Apodaca², Ana Barrera-Vargas³, Jorge Alcocer-Varela³ and Diana Gómez-Martín³, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Posterior reversible encephalopathy syndrome (PRES) is a well-known but rare complication in systemic lupus erythematosus (SLE) patients (
Abstract Number: 1658 • 2014 ACR/ARHP Annual Meeting
Renal Thrombotic Microangiopathy in Systemic Lupus Erythematosus: Novel Risk Factors and Clinical Outcomes
Ana Barrera-Vargas¹, Rodrigo Rosado-Canto², Javier Merayo-Chalico³, Jorge Alcocer-Varela¹ and Diana Gómez-Martín¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Thrombotic microangiopathy (TMA) is characterized by microvascular occlusion, systemic or intrarenal platelet aggregation and mechanical injury to erythrocytes. It is a pathological endpoint that…
Abstract Number: 1579 • 2013 ACR/ARHP Annual Meeting
Novel Risk Factors For Thrombotic Thrombocytopenic Purpura In Systemic Lupus Erythematosus patients
Javier Merayo-Chalico¹, Diana Gómez-Martín², Roberta Demichelis-Gómez³, Sandra Rajme-Lopez², Luis Aparicio-Vera² and Jorge Alcocer-Varela², ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico city, Mexico, ³Haematology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico city, Mexico
Background/Purpose: Thrombotic thrombocytopenic purpura (TTP) is an uncommon disease characterized by thrombocytopenia and microangiopathic hemolytic anemia and, in some cases, fever, neurologic and/or renal abnormalities.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].